Page last updated: 2024-11-11

6-(1h-imidazol-1-yl)-7-nitro-2,3(1h,4h)-quinoxalinedione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione: inhibits AMPA receptor binding; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5486547
CHEMBL ID3400490
MeSH IDM0228432

Synonyms (33)

Synonym
ym-90k
2,3-quinoxalinedione, 1,4-dihydro-6-(1h-imidazol-1-yl)-7-nitro-, monohydrochloride
ym 900
6-(1h-imidazol-1-yl)-7-nitro-2,3(1h,4h)-quinoxalinedione
ym90k
1,4-dihydro-6-(1h-imidazol-1-yl)-7-nitro-2,3-quinoxalinedione monohydrochloride
unii-uaexclwi0q
6-(1h-imidazol-1-yl)-7-nitro-2,3(1h,4h)-quinoxalinedione hydrochloride
uaexclwi0q ,
154164-30-4
1,4-dihydro-6-(1h-imidazol-1-yl)-7-nitro-2,3-quinoxalinedione hydrochloride
6-imidazol-1-yl-7-nitro-1,4-dihydro-quinoxaline-2,3-dione hydrochloride
ym 90k hydrochloride
AKOS024457249
DTXSID00165547
CHEMBL3400490
ym-90k hydrochloride
EX-A113
HY-15071
CS-0003739
J-009073
2,3-quinoxalinedione, 1,4-dihydro-6-(1h-imidazol-1-yl)-7-nitro-, hydrochloride (1:1)
ym 90k hcl
BCP06490
ym-90k hcl
ym90k hydrochloride
6-(1h-imidazol-1-yl)-7-nitro-2,3(1h,4h)-quinoxalinedione monohydrochloride
F17408
FT-0758749
Q12073018
6-imidazol-1-yl-7-nitro-1,4-dihydroquinoxaline-2,3-dione;hydrochloride
6-(1h-imidazol-1-yl)-7-nitro-2,3(1h,4h)-
AC-36793

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" YM90K showed neither significant adverse reactions nor severe abnormalities in physical and laboratory examinations of the study participants and demonstrated safety and pharmacokinetic profiles compatible with clinical use."( Pharmacokinetics and safety of the novel amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist YM90K in healthy men.
Homma, M; Ikeda, Y; Kondo, K; Nakashima, M; Teraya, Y; Uematsu, T; Umemura, K; Yoshida, H, 1997
)
0.3

Pharmacokinetics

ExcerptReferenceRelevance
" YM90K showed neither significant adverse reactions nor severe abnormalities in physical and laboratory examinations of the study participants and demonstrated safety and pharmacokinetic profiles compatible with clinical use."( Pharmacokinetics and safety of the novel amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist YM90K in healthy men.
Homma, M; Ikeda, Y; Kondo, K; Nakashima, M; Teraya, Y; Uematsu, T; Umemura, K; Yoshida, H, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" YM90K induced a parallel and rightward shift of both kainate and AMPA dose-response curves."( The AMPA-receptor antagonist YM90K reduces AMPA receptor-mediated excitotoxicity in rat hippocampal cultures.
Ohno, K; Okada, M; Sakamoto, S; Tsutsumi, R; Yamaguchi, T, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1194211Anticonvulsant activity in po dosed ICR mouse assessed as protection from maximal electroshock-induced seizure measured after 60 mins post dose2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Synthesis, structure-activity relationships, and anticonvulsant activities of 2-amino-4H-pyrido[3,2-e][1,3]thiazin-4-one derivatives as orally active AMPA receptor antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's28 (77.78)18.2507
2000's6 (16.67)29.6817
2010's2 (5.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.60 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.78%)5.53%
Reviews1 (2.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]